Alkermes (ALKS)
(Delayed Data from NSDQ)
$23.75 USD
-0.27 (-1.12%)
Updated May 28, 2024 04:00 PM ET
After-Market: $23.73 -0.02 (-0.08%) 6:56 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Alkermes plc [ALKS]
Reports for Purchase
Showing records 101 - 120 ( 287 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
4230 Shows Promise in Advanced Tumors, No New Safety Signals Observed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Solid 2Q20 and Reinstatement of Guidance as Landscape Solidifies; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Solid 1Q, Covid-19 Clouds Visibility, Resulting in Guidance Being Pulled
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Renewed Focus on Profitability Underwhelms for 2020; We Stay at Neutral, Nudge Target Down to $25 from $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D